Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

HDAC10 suppresses anti-tumour immunity by inhibiting ILF3-CXCL9 axis to block CD8+ T cell infiltration and activation in bladder cancer.

Cancer letters·2026

Same author

The heat-ramp method to study regulated cell death in a pathogenic yeast Cryptococcus neoformans.

Methods in cell biology·2026

Same author

From Self-Esteem and Academic Performance to Anxiety: A Cross-Lagged Study of Chinese First-Generation College Students.

Behavioral sciences (Basel, Switzerland)·2026

Same author

Numerical and experimental assessment of implant-induced thermal risks during electrosurgical procedures.

Biomedical physics & engineering express·2026

Same author

Depression and general self-efficacy among first-generation college students in China: a longitudinal analysis.

Scientific reports·2026

Same author

Living with a spouse or partner, material hardship, and mental distress among men and women during the COVID-19 pandemic in New York City.

Frontiers in public health·2026

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Ion sequential therapy aligned with pathological changes enhances cardiac function after myocardial infarction.

Yiming Zhong¹, Zhaowenbin Zhang², Shixing Huang¹

¹Department of Cardiovascular Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.

Cell Reports. Medicine

|June 11, 2026

Summary

This study introduces a novel sequential zinc-copper therapy to improve heart function after myocardial infarction (MI). The treatment targets circadian rhythm genes and uses a special device for localized delivery, reducing side effects.

Keywords:

copper ion epicardial device myocardial infarction sequential therapy zinc ion

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Myocardial Infarction and Functional Outcome Assessment in Pigs

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

Related Experiment Videos

Last Updated: Jun 13, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Myocardial Infarction and Functional Outcome Assessment in Pigs

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

Area of Science:

Cardiovascular Biology
Trace Element Metabolism
Chronobiology

Background:

Myocardial infarction (MI) causes trace element imbalances, worsening cardiac remodeling.
Understanding zinc (Zn) and copper (Cu) dynamics post-MI is crucial for therapeutic development.

Purpose of the Study:

To map Zn and Cu ion dynamics after MI.
To develop a sequential Zn-Cu therapy for post-MI cardiac repair.
To investigate the role of the PER2 gene in therapeutic efficacy.

Main Methods:

Spatiotemporal mapping of Zn and Cu ions post-MI.
Design and implementation of a sequential Zn-Cu therapeutic regimen.
Engineering a perfusable epicardial device (PerMed) for localized ion delivery.
Assessment of cardiac function and PER2 gene modulation.

Main Results:

Sequential Zn-Cu therapy effectively modulated ion levels and improved cardiac function.
Therapeutic efficacy was linked to precise modulation of the period circadian protein homolog 2 (PER2) gene.
The PerMed device maintained stable, localized ion concentrations, minimizing systemic effects.

Conclusions:

A temporally controlled Zn-Cu therapy can attenuate post-infarction heart failure.
Targeting circadian rhythm genes like PER2 is a viable strategy for cardiomyocyte repair.
The PerMed device offers a targeted approach for localized trace element delivery in cardiovascular disease.